Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View

Metabolic syndrome (MetS) implies different conditions where insulin resistance constitutes a major hallmark of the disease. The disease incurs a high risk for the development of cardiovascular complications, and takes its toll in regard to the gut–liver axis (pancreas, primary liver and colorectal)...

Descripción completa

Detalles Bibliográficos
Autores: Jeri Apaza, César, Cerezo, Juan Francisco, García-Tejedor, Aurora, Giménez-Bastida, J. A., Laparra, José Moisés
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/367015
Acceso en línea:http://hdl.handle.net/10261/367015
Access Level:acceso abierto
Palabra clave:Metabolic syndrome
Insulin resistance
Macrophage
Immunonutrition
Obesity
Type 2 diabetes
id ES_66496b2ae5bbb39d9f72044e2ef65d4a
oai_identifier_str oai:digital.csic.es:10261/367015
network_acronym_str ES
network_name_str España
repository_id_str
spelling Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional ViewJeri Apaza, CésarCerezo, Juan FranciscoGarcía-Tejedor, AuroraGiménez-Bastida, J. A.Laparra, José MoisésMetabolic syndromeInsulin resistanceMacrophageImmunonutritionObesityType 2 diabetesMetabolic syndrome (MetS) implies different conditions where insulin resistance constitutes a major hallmark of the disease. The disease incurs a high risk for the development of cardiovascular complications, and takes its toll in regard to the gut–liver axis (pancreas, primary liver and colorectal)-associated immunity. The modulation of immunometabolic responses by immunonutritional factors (IFs) has emerged as a key determinant of the gut–liver axis’ metabolic and immune health. IFs from plant seeds have shown in vitro and pre-clinical effectiveness primarily in dealing with various immunometabolic and inflammatory diseases. Only recently have immunonutritional studies established the engagement of innate intestinal immunity to effectively control immune alterations in inflamed livers preceding the major features of the MetS. However, integrative analyses and the demonstration of causality between IFs and specific gut–liver axis-associated immunometabolic imbalances for the MetS remain ill-defined in the field. Herein, a better understanding of the IFs with a significant role in the MetS, as well as within the dynamic interplay in the functional differentiation of innate immune key effectors (i.e., monocytes/macrophages), worsening or improving the disease, could be of crucial relevance. The development of an adequate intermediary phenotype of these cells can significantly contribute to maintaining the function of Tregs and innate lymphoid cells for the prevention and treatment of MetS and associated comorbidities.This work was financially supported by grants Food4ImNut [PID2019-107650RB-C22, Ministry of Science, Innovation and Universities—MICIU] and grant RyC2021-032111-I funded by MCIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”.Peer reviewedMultidisciplinary Digital Publishing InstituteMinisterio de Ciencia, Innovación y Universidades (España)Agencia Estatal de Investigación (España)European CommissionConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2024202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/367015reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-107650RB-C22info:eu-repo/grantAgreement/AEI//RyC2021-032111-Ihttps://doi.org/10.3390/biomedicines12081825Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3670152026-05-22T06:33:51Z
dc.title.none.fl_str_mv Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
title Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
spellingShingle Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
Jeri Apaza, César
Metabolic syndrome
Insulin resistance
Macrophage
Immunonutrition
Obesity
Type 2 diabetes
title_short Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
title_full Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
title_fullStr Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
title_full_unstemmed Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
title_sort Revisiting the Immunometabolic Basis for the Metabolic Syndrome from an Immunonutritional View
dc.creator.none.fl_str_mv Jeri Apaza, César
Cerezo, Juan Francisco
García-Tejedor, Aurora
Giménez-Bastida, J. A.
Laparra, José Moisés
author Jeri Apaza, César
author_facet Jeri Apaza, César
Cerezo, Juan Francisco
García-Tejedor, Aurora
Giménez-Bastida, J. A.
Laparra, José Moisés
author_role author
author2 Cerezo, Juan Francisco
García-Tejedor, Aurora
Giménez-Bastida, J. A.
Laparra, José Moisés
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia, Innovación y Universidades (España)
Agencia Estatal de Investigación (España)
European Commission
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Metabolic syndrome
Insulin resistance
Macrophage
Immunonutrition
Obesity
Type 2 diabetes
topic Metabolic syndrome
Insulin resistance
Macrophage
Immunonutrition
Obesity
Type 2 diabetes
description Metabolic syndrome (MetS) implies different conditions where insulin resistance constitutes a major hallmark of the disease. The disease incurs a high risk for the development of cardiovascular complications, and takes its toll in regard to the gut–liver axis (pancreas, primary liver and colorectal)-associated immunity. The modulation of immunometabolic responses by immunonutritional factors (IFs) has emerged as a key determinant of the gut–liver axis’ metabolic and immune health. IFs from plant seeds have shown in vitro and pre-clinical effectiveness primarily in dealing with various immunometabolic and inflammatory diseases. Only recently have immunonutritional studies established the engagement of innate intestinal immunity to effectively control immune alterations in inflamed livers preceding the major features of the MetS. However, integrative analyses and the demonstration of causality between IFs and specific gut–liver axis-associated immunometabolic imbalances for the MetS remain ill-defined in the field. Herein, a better understanding of the IFs with a significant role in the MetS, as well as within the dynamic interplay in the functional differentiation of innate immune key effectors (i.e., monocytes/macrophages), worsening or improving the disease, could be of crucial relevance. The development of an adequate intermediary phenotype of these cells can significantly contribute to maintaining the function of Tregs and innate lymphoid cells for the prevention and treatment of MetS and associated comorbidities.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/367015
url http://hdl.handle.net/10261/367015
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-107650RB-C22
info:eu-repo/grantAgreement/AEI//RyC2021-032111-I
https://doi.org/10.3390/biomedicines12081825
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409804832735232
score 15.812429

Similares en LA Referencia